Cargando…
Randomized phase II study of nintedanib with or without pirfenidone in patients with idiopathic pulmonary fibrosis who experienced disease progression during prior pirfenidone administration
INTRODUCTION: A subgroup analysis of the CAPACITY and ASCEND trials showed that pirfenidone use beyond disease progression reduced the risk of subsequent forced vital capacity (FVC) decline and death. Our study aimed to compare the efficacy and safety of nintedanib with or without pirfenidone for pa...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9276254/ https://www.ncbi.nlm.nih.gov/pubmed/35665728 http://dx.doi.org/10.1097/MD.0000000000029232 |
_version_ | 1784745680145743872 |
---|---|
author | Ikeda, Satoshi Sekine, Akimasa Baba, Tomohisa Kato, Terufumi Katano, Takuma Tabata, Erina Shintani, Ryota Yamakawa, Hideaki Oda, Tsuneyuki Okuda, Ryo Kitamura, Hideya Iwasawa, Tae Takemura, Tamiko Ogura, Takashi |
author_facet | Ikeda, Satoshi Sekine, Akimasa Baba, Tomohisa Kato, Terufumi Katano, Takuma Tabata, Erina Shintani, Ryota Yamakawa, Hideaki Oda, Tsuneyuki Okuda, Ryo Kitamura, Hideya Iwasawa, Tae Takemura, Tamiko Ogura, Takashi |
author_sort | Ikeda, Satoshi |
collection | PubMed |
description | INTRODUCTION: A subgroup analysis of the CAPACITY and ASCEND trials showed that pirfenidone use beyond disease progression reduced the risk of subsequent forced vital capacity (FVC) decline and death. Our study aimed to compare the efficacy and safety of nintedanib with or without pirfenidone for patients with idiopathic pulmonary fibrosis (IPF) who experienced disease progression during previous pirfenidone therapy. METHODS: In this randomized, open-label, selection design phase II trial, patients with IPF and a ≥5% relative decline in FVC within 6 months of the pirfenidone administration period were randomly assigned to nintedanib (switch group) or nintedanib plus pirfenidone (combination group). The primary endpoint was the incidence of a ≥5% relative decline in FVC or death during the first 6 months. RESULTS: Only 7 patients were enrolled (4 in the switch group and 3 in the combination group). Although the switch group continued with nintedanib for 1 year or more, 2 patients (66.7%) in the combination group discontinued nintedanib within 6 months due to severe adverse events. Given the slow case registration and safety concerns in the combination group, the trial was terminated without extending the registration. The incidence of a ≥5% relative decline in FVC during the first 6 months was 50.0% in the switch group and 66.7% in the combination group. There were no deaths during the observation period. CONCLUSIONS: Clinical trials verifying the use of pirfenidone after disease progression in IPF may be difficult to enroll patients. Definitive conclusions on both safety and efficacy cannot be drawn from the results of this study alone. TRIAL REGISTRATION: UMIN Clinical Trial Registry; registration number, UMIN000019436; date of first registration, 21/10/2015; https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000022471. |
format | Online Article Text |
id | pubmed-9276254 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-92762542022-07-13 Randomized phase II study of nintedanib with or without pirfenidone in patients with idiopathic pulmonary fibrosis who experienced disease progression during prior pirfenidone administration Ikeda, Satoshi Sekine, Akimasa Baba, Tomohisa Kato, Terufumi Katano, Takuma Tabata, Erina Shintani, Ryota Yamakawa, Hideaki Oda, Tsuneyuki Okuda, Ryo Kitamura, Hideya Iwasawa, Tae Takemura, Tamiko Ogura, Takashi Medicine (Baltimore) 6700 INTRODUCTION: A subgroup analysis of the CAPACITY and ASCEND trials showed that pirfenidone use beyond disease progression reduced the risk of subsequent forced vital capacity (FVC) decline and death. Our study aimed to compare the efficacy and safety of nintedanib with or without pirfenidone for patients with idiopathic pulmonary fibrosis (IPF) who experienced disease progression during previous pirfenidone therapy. METHODS: In this randomized, open-label, selection design phase II trial, patients with IPF and a ≥5% relative decline in FVC within 6 months of the pirfenidone administration period were randomly assigned to nintedanib (switch group) or nintedanib plus pirfenidone (combination group). The primary endpoint was the incidence of a ≥5% relative decline in FVC or death during the first 6 months. RESULTS: Only 7 patients were enrolled (4 in the switch group and 3 in the combination group). Although the switch group continued with nintedanib for 1 year or more, 2 patients (66.7%) in the combination group discontinued nintedanib within 6 months due to severe adverse events. Given the slow case registration and safety concerns in the combination group, the trial was terminated without extending the registration. The incidence of a ≥5% relative decline in FVC during the first 6 months was 50.0% in the switch group and 66.7% in the combination group. There were no deaths during the observation period. CONCLUSIONS: Clinical trials verifying the use of pirfenidone after disease progression in IPF may be difficult to enroll patients. Definitive conclusions on both safety and efficacy cannot be drawn from the results of this study alone. TRIAL REGISTRATION: UMIN Clinical Trial Registry; registration number, UMIN000019436; date of first registration, 21/10/2015; https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000022471. Lippincott Williams & Wilkins 2022-06-03 /pmc/articles/PMC9276254/ /pubmed/35665728 http://dx.doi.org/10.1097/MD.0000000000029232 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/) |
spellingShingle | 6700 Ikeda, Satoshi Sekine, Akimasa Baba, Tomohisa Kato, Terufumi Katano, Takuma Tabata, Erina Shintani, Ryota Yamakawa, Hideaki Oda, Tsuneyuki Okuda, Ryo Kitamura, Hideya Iwasawa, Tae Takemura, Tamiko Ogura, Takashi Randomized phase II study of nintedanib with or without pirfenidone in patients with idiopathic pulmonary fibrosis who experienced disease progression during prior pirfenidone administration |
title | Randomized phase II study of nintedanib with or without pirfenidone in patients with idiopathic pulmonary fibrosis who experienced disease progression during prior pirfenidone administration |
title_full | Randomized phase II study of nintedanib with or without pirfenidone in patients with idiopathic pulmonary fibrosis who experienced disease progression during prior pirfenidone administration |
title_fullStr | Randomized phase II study of nintedanib with or without pirfenidone in patients with idiopathic pulmonary fibrosis who experienced disease progression during prior pirfenidone administration |
title_full_unstemmed | Randomized phase II study of nintedanib with or without pirfenidone in patients with idiopathic pulmonary fibrosis who experienced disease progression during prior pirfenidone administration |
title_short | Randomized phase II study of nintedanib with or without pirfenidone in patients with idiopathic pulmonary fibrosis who experienced disease progression during prior pirfenidone administration |
title_sort | randomized phase ii study of nintedanib with or without pirfenidone in patients with idiopathic pulmonary fibrosis who experienced disease progression during prior pirfenidone administration |
topic | 6700 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9276254/ https://www.ncbi.nlm.nih.gov/pubmed/35665728 http://dx.doi.org/10.1097/MD.0000000000029232 |
work_keys_str_mv | AT ikedasatoshi randomizedphaseiistudyofnintedanibwithorwithoutpirfenidoneinpatientswithidiopathicpulmonaryfibrosiswhoexperienceddiseaseprogressionduringpriorpirfenidoneadministration AT sekineakimasa randomizedphaseiistudyofnintedanibwithorwithoutpirfenidoneinpatientswithidiopathicpulmonaryfibrosiswhoexperienceddiseaseprogressionduringpriorpirfenidoneadministration AT babatomohisa randomizedphaseiistudyofnintedanibwithorwithoutpirfenidoneinpatientswithidiopathicpulmonaryfibrosiswhoexperienceddiseaseprogressionduringpriorpirfenidoneadministration AT katoterufumi randomizedphaseiistudyofnintedanibwithorwithoutpirfenidoneinpatientswithidiopathicpulmonaryfibrosiswhoexperienceddiseaseprogressionduringpriorpirfenidoneadministration AT katanotakuma randomizedphaseiistudyofnintedanibwithorwithoutpirfenidoneinpatientswithidiopathicpulmonaryfibrosiswhoexperienceddiseaseprogressionduringpriorpirfenidoneadministration AT tabataerina randomizedphaseiistudyofnintedanibwithorwithoutpirfenidoneinpatientswithidiopathicpulmonaryfibrosiswhoexperienceddiseaseprogressionduringpriorpirfenidoneadministration AT shintaniryota randomizedphaseiistudyofnintedanibwithorwithoutpirfenidoneinpatientswithidiopathicpulmonaryfibrosiswhoexperienceddiseaseprogressionduringpriorpirfenidoneadministration AT yamakawahideaki randomizedphaseiistudyofnintedanibwithorwithoutpirfenidoneinpatientswithidiopathicpulmonaryfibrosiswhoexperienceddiseaseprogressionduringpriorpirfenidoneadministration AT odatsuneyuki randomizedphaseiistudyofnintedanibwithorwithoutpirfenidoneinpatientswithidiopathicpulmonaryfibrosiswhoexperienceddiseaseprogressionduringpriorpirfenidoneadministration AT okudaryo randomizedphaseiistudyofnintedanibwithorwithoutpirfenidoneinpatientswithidiopathicpulmonaryfibrosiswhoexperienceddiseaseprogressionduringpriorpirfenidoneadministration AT kitamurahideya randomizedphaseiistudyofnintedanibwithorwithoutpirfenidoneinpatientswithidiopathicpulmonaryfibrosiswhoexperienceddiseaseprogressionduringpriorpirfenidoneadministration AT iwasawatae randomizedphaseiistudyofnintedanibwithorwithoutpirfenidoneinpatientswithidiopathicpulmonaryfibrosiswhoexperienceddiseaseprogressionduringpriorpirfenidoneadministration AT takemuratamiko randomizedphaseiistudyofnintedanibwithorwithoutpirfenidoneinpatientswithidiopathicpulmonaryfibrosiswhoexperienceddiseaseprogressionduringpriorpirfenidoneadministration AT oguratakashi randomizedphaseiistudyofnintedanibwithorwithoutpirfenidoneinpatientswithidiopathicpulmonaryfibrosiswhoexperienceddiseaseprogressionduringpriorpirfenidoneadministration |